Company News

AgroSpheres, a biotechnology leader in sustainable crop protection and crop health, today announced that its first biofungicide, powered by the novel AgriCell technology, has received approval from the Environmental Protection Agency (EPA) following a comprehensive review. This approval allows the company to commence commercial production, bringing its innovative bioplatform technology directly to growers. The proprietary …

LumaCyte, a leader in advanced cellular analysis and precision bioanalytics, proudly announces the launch of its groundbreaking cell therapy application for predictive CAR T donor analytics. Leveraging its novel Laser Force Cytology™ (LFC™) technology and Radiance® instrument, LumaCyte uncovers deep data insights into highly variable and complex patient and donor cellular starting material, enabling cell …

ReAlta Life Sciences, Inc. (“ReAlta” or the “Company”), a clinical-stage biopharmaceutical company dedicated to saving lives by rebalancing the inflammatory response to address rare and acute inflammatory diseases, announced that Peter Ho, Ph.D., has joined the Company as Head of Business Development and Corporate Strategy. “I am thrilled to have Peter join our executive team …

Activation Capital, an innovation ecosystem development organization, has announced the selection of 10 fast-growing startups from across the country for the inaugural Frontier BioHealth program, which commenced with an in-person gathering on August 8-9, 2024. Each company will benefit from highly specialized training, targeted mentorship, and extensive relationship-building opportunities to accelerate its growth in the life …

ReAlta Life Sciences, Inc. (“ReAlta” or the “Company”), a clinical-stage biopharmaceutical company dedicated to saving lives by rebalancing the inflammatory response to address rare and acute inflammatory diseases, today announced two distinguished biopharmaceutical veterans to lead the Company: David Marek appointed as Chief Executive Officer and Paolo Martini, Ph.D., appointed as Chief Research and Development …

The Alliance for Pediatric Device Innovation (APDI), a nonprofit consortium led by Children’s National Hospital and funded by the Food and Drug Administration (FDA), announces today it is partnering with Additional Ventures, a nonprofit foundation focused on accelerating research progress and improving clinical care for individuals born with single ventricle heart defects, to solicit proposals …

ReAlta Life Sciences, Inc., a clinical-stage biotech company dedicated to saving lives by rebalancing the inflammatory response to address rare and acute inflammatory diseases, announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation and Fast Track Designation to RLS-0071, the Company’s lead therapeutic candidate, for the treatment of hospitalized patients …

Rivus Pharmaceuticals Inc., a clinical-stage biopharmaceutical company dedicated to improving metabolic health, today announced its Phase 2a HuMAIN clinical trial of HU6 in patients with obesity-related heart failure with preserved ejection fraction (HFpEF) met its primary endpoint of weight reduction. HU6, an oral, once-daily potentially first-in-class investigational treatment, is a Controlled Metabolic Accelerator (CMA), which …

Many ingredients that make up the pharmaceuticals Americans rely on are manufactured overseas. When supply chain issues or shortages occur, as witnessed during the COVID pandemic, it can negatively impact millions of Americans and affect national security. The White House issued an Executive Order in 2022 to stimulate U.S. biomanufacturing. Increasing American biomanufacturing, will provide …

Governor Glenn Youngkin  announced that 11 companies across the Commonwealth have graduated from the Virginia Economic Development Partnership’s (VEDP) Virginia Leaders in Export Trade (VALET) program and 14 companies have joined the two-year program. VALET, which now has 402 graduated companies, assists Virginia exporters that have firmly established domestic operations and are committed to international …

The Virginia Biotechnology Research Park Authority Board appointed Robert Ward as interim president and chief executive officer of Activation Capital, an innovation ecosystem development organization, effective today. Ward is a senior executive with over 25 years of experience leading organizations, driving strategy and innovation, developing high performing teams and executing complex transactions. Ward has served …

Nancy Howell Agee, who led Carilion through more than a decade of transformative change, will step down as CEO Sept. 30. Steve Arner, who was promoted to president in May 2023, will succeed Agee and become president and CEO Oct. 1. The leadership transition comes after Agee’s long and distinguished career at Carilion, beginning as …

AMPEL BioSolutions, with collaborators Lupus Therapeutics and Aker Biomarine, revealed peer-reviewed results that supplementation with Omega3-rich Krill Oil improves disease activity of autoimmune Lupus patients. Omega3 lipids called polyunsaturated fatty acids (PUFAs) that are found in microscopic shrimp-like crustaceans called Krill from the waters around Antarctica are key to maintaining a low inflammatory state.  Some …

Two privately held specialty chemical firms that provide high-purity materials and services for chemical applications, from renewable energy to food and beverages and consumer safety, are combining their capabilities to serve new and expanding precision markets. IV Labs Inc., the parent company of Inorganic Ventures, has acquired PURE Analytical Laboratories, one of the few companies that …

BrightSpec, the market leader in Molecular Rotational Resonance (MRR) spectroscopy solutions, announced the appointment of two new executives to drive the commercialization of their growing portfolio of precision instruments and analytical tools. BrightSpec develops and commercializes instruments that harness the power of MRR spectroscopy, an innovative approach to rapidly and definitively characterize the unique three-dimensional …

BIO-CAT, an industry-leading enzyme supplier headquartered in Virginia, is excited to announce the publication of a groundbreaking safety clinical trial manuscript featuring its proprietary ingredient, OPTIZIOME® Inulinase  (now marketed as OPTIZIOME® Fructanase), in Gastro Hep Advances. Fructanase, also known as inulinase, was developed to address the unintended consequences of digestive discomfort from certain foods, more …

ReAlta Life Sciences, Inc., a mid-stage clinical biotech company dedicated to saving lives by rebalancing the inflammatory response to address life-threatening diseases,  announced the appointment of Emma Reeve to its Board of Directors, effective immediately. “We are very pleased to welcome Emma Reeve to our Board of Directors,” said Buzz Heidt, Chairman of ReAlta’s Board …

CEL-SCI Corporation announced that Robert (“Bob”) Watson, who has served as a Director of the Company since 2017, has been appointed Chairperson of the Board. Bob is an accomplished business leader who began his career as an investment banker. With over four decades of experience across various healthcare markets, Bob brings extensive expertise in capital …

Contraline, a clinical-stage biotechnology company, has announced promising initial safety and efficacy results from its First-in-Human clinical trial. The trial, which is evaluating the safety and preliminary efficacy of Contraline’s ADAM™, a non-permanent male contraceptive, has had its first patients demonstrate 12 months of efficacy in the study. ADAM™ is a water-soluble, biocompatible, and non-permanent …

Chandra Briggman is exiting her role as president and CEO of Richmond’s Activation Capital. The independent authority of Virginia that promotes research, commercialization and innovation ecosystem development in the Richmond region said Monday that Briggman is leaving “to pursue new opportunities to build innovation ecosystems and drive economic development.” She’s been in the role a …

Roquette, a global leader in plant-based ingredients and a leading provider of pharmaceutical excipients, and Bonumose, a pioneer in enzymatic solutions for rare monosaccharide production, are pleased to announce the signing of a Cooperation Agreement that aims to advance the development of tagatose, a natural-origin sweetener with clinically proven health benefits. This collaboration combines Roquette’s …

The Virginia Catalyst, also known as the Virginia Biosciences Health Research Corporation (VBHRC), today announced that it has awarded $3.18 million in grants to four life and bioscience projects in the Commonwealth of Virginia. These grants, which will be met with significant matching funds from partner companies, were awarded through Grant Round 16. “Powerful collaborations …

Quoin Pharmaceuticals Ltd., a clinical stage specialty pharmaceutical company focused on rare and orphan diseases,  announced that it will expand its ongoing Netherton Syndrome clinical studies to include international sites. The first international site will be opened at a research hospital in Saudi Arabia. This hospital is currently treating a number of Netherton patients who …

PAK BioSolutions announced that it has raised $12M from Arboretum Ventures, BroadOak Capital Partners, and other investors to expand commercial and product development efforts for its line of automated continuous manufacturing systems for biologics. The PAK Pilot System is capable of processing 50-500L of cell culture per day, addressing a major segment of the biopharmaceutical …